There is no cure for frontotemporal dementia (FTD) and no way to slow or prevent it, according to the U.S. National Institute on Aging. No drug is approved to slow it. FTD damages the front and side parts of the brain, changing behavior, personality, language or movement. About 60% of people with FTD are 45 to 64 years old. Most current research targets the inherited form caused by changes in the GRN gene, which lowers a protein called progranulin. The largest trial so far, latozinemab's Phase 3 INFRONT-3, raised progranulin but did not slow the disease. Our view: a treatment that slows FTD has not been shown yet. Medicines, therapy and caregiver support can ease some symptoms.
This is Cure Checker's editorial assessment of published evidence, not medical advice. Care decisions belong with an FTD-experienced medical team.
Please read first. This is an AI-generated hypothesis, written by Cure Checker's AI from published research. It is speculation, not an established finding. It is not a recommendation, not a prediction that a cure exists, and not medical advice. No doctors or scientists have reviewed it, and it may be wrong. Never start, stop, change or delay any treatment because of it. Talk with your FTD-experienced care team.
Could a spinal-fluid test of lysosome health (for example, BMP levels), which does not yet exist for routine use, show whether a progranulin treatment is repairing brain cells better than blood progranulin does? And could a treatment that brings it back to normal, started in GRN carriers whose markers show the disease beginning, slow FTD where raising blood progranulin later did not?
What would prove it wrong: if spinal-fluid lysosome markers do not track the disease in GRN carriers, or if normalizing them does not slow brain shrinkage or symptoms.
Hypothesis written October 6, 2026. Cure Checker's AI will revisit it when major new evidence appears.
Newest first. Updated each morning as results, trial launches and papers are published.
A review pooling 23 studies and 3,670 people found AI models reading brain scans told FTD apart from healthy people with about 91% sensitivity and 92% specificity. They did best for semantic variant primary progressive aphasia. The authors warn that many studies had a high risk of bias and that tests in new groups of patients are needed before clinic use. This is about diagnosis, not treatment.
In 21 people with behavioral-variant FTD and 25 matched controls, the FTD group did worse on tests of visual and spatial imagination and visuospatial working memory. Better general thinking scores went with better results on most of the tests. It is a small study that describes a symptom and does not test a treatment.
Brain scans of 107 people with early behavioral-variant FTD and 100 healthy controls linked the size of certain back cerebellum regions (especially right Crus I and II) to trouble with theory of mind, the ability to work out what others think. It shows a link, not cause and effect, and no treatment was tested.
The peer-reviewed paper confirms the April results. Latozinemab kept progranulin levels up in blood and spinal fluid in people with symptomatic FTD-GRN, but did not slow disease progression on clinical or biomarker measures. No safety concerns were found. Alector employees are among the authors.
Researchers compared PET scans taken in life with brain tissue examined after death in 10 people with FTD and 5 controls. The scan signal tracked activated immune cells called microglia. This supports using the scan to track brain inflammation. It is a very small study and does not test a treatment.
In blood samples from two groups (415 people with FTD and 223 controls in total), people with FTD showed higher epigenetic age acceleration, a DNA-based measure of biological aging. About half of the difference was linked to smoking-related markers. Higher inflammation and blood-sugar markers were also seen. This is an association, not a cause or a treatment.
Researchers searched trial registries for active studies up to May 31, 2026 and found 38 in frontotemporal lobar degeneration: 19 drug trials and 19 brain-stimulation trials. Only 1 was Phase 3, and most drug work targeted progranulin or tau. The authors say the pipeline is still mostly early stage and no disease-modifying therapy is approved. This is a review, not a new trial result.
Penn and the University of Miami will follow 330 people over 45 who carry the C9orf72 change, at 14 sites, using cognitive and movement tests, MRI and body-fluid tests. The goal is reliable early markers so future prevention trials are possible. It is not a treatment trial.
In a Phase 1 trial, 79 healthy adults took VES001 or placebo. There were no deaths, serious side effects or stops because of side effects; headache and fatigue were mild. Twice-daily dosing raised progranulin in blood (peak 49% above baseline) and in spinal fluid (18%). Participants were healthy volunteers, not people with FTD, so this shows the drug works on its target but not that it helps patients.
In progranulin-deficient mice, a gene therapy making progranulin with its sortilin-binding end blocked reached higher levels and corrected more brain and behavior problems than the standard version. Animal study only.
The FDA granted DNL593 orphan drug designation for FTD-GRN in August. Denali moved expected Phase 1/2 results from the end of 2026 to 2027 to allow longer follow-up of biomarkers such as neurofilament light.
Among 278 people with C9orf72, GRN or MAPT changes, median survival was 6.94 years from first symptoms. Older age at onset, FTD with ALS, and movement or language as the first symptom were linked to shorter survival.
Passage Bio stopped its Phase 1/2 trial of PBFT02 after the FDA would not accept a single-arm design for approval and asked for a randomized trial.
In people with moderate disease, brain shrinkage over 12 months was 54% less than in untreated natural-history patients (4.6% vs 9.9%), and blood neurofilament light stayed stable. Two people had serious side effects linked to treatment earlier in the trial. Small, uncontrolled data (company release).
In 102 people with symptoms of FTD-GRN, latozinemab raised blood progranulin by 165% over placebo at 96 weeks but did not slow decline. Neurofilament light, GFAP and MRI showed no treatment effect. No safety signals were seen.
Takeda ended its collaboration with Denali on DNL593. Denali said the decision was strategic and not related to efficacy or safety data, and it kept developing the drug.
ASPIRE-FTD has dosed 12 people in three dose groups. CSF progranulin rose with dose, and no serious side effects were linked to AVB-101. The trial runs at 20 sites in the U.S., UK, Canada and six European countries (company release).
Lilly discontinued LY3884963 (formerly PR006) "due to a lack of compelling efficacy," and said the decision was not due to safety. People already treated stay in safety follow-up.
In a small crossover trial, oxytocin was safe and caregivers reported more social engagement. It did not improve the main tests of emotion recognition, and recognizing harmful intentions got worse.
A technical report on three ASPIRE-FTD patients who had MRI-guided infusions into both thalami. There were no surgical complications.
The Phase 3 trial met its progranulin goal but not its clinical goal of slowing FTD-GRN. Alector stopped the open-label extension and continuation study.
No treatment slows FTD yet. Symptom medicines and therapy help some people. Here is where the disease-slowing candidates stand, including the failures.
SSRI antidepressants are commonly prescribed for disinhibition and impulsive behavior. European experts recommend trazodone for restlessness. Trial evidence for these uses is limited, and none is FDA-approved for FTD.
Speech therapy with someone who knows primary progressive aphasia helps people keep communicating. Physical and occupational therapy may give modest relief from movement symptoms.
An antibody meant to raise progranulin. In 102 people with symptoms, it raised blood progranulin but did not slow the disease over 96 weeks. Its extension studies were stopped.
Lilly stopped LY3884963 (PR006) in February 2026 for lack of convincing benefit. Passage Bio reported encouraging biomarker results for PBFT02, then closed its trial in May 2026 after the FDA asked for a randomized trial.
Delivered by surgery into the thalamus. Twelve people had been dosed by March 2026, the company reported, with higher spinal-fluid progranulin at higher doses and no serious side effects linked to treatment (company release).
Progranulin built to cross into the brain from an IV infusion. Enrollment is complete with 40 people with FTD-GRN, and results are now expected in 2027.
| Treatment | For | What it does |
|---|---|---|
| SSRI antidepressants | Disinhibition, impulsivity | Commonly prescribed to ease these behaviors. Not FDA-approved for FTD. |
| Trazodone | Restlessness | Recommended by European expert consensus for motor restlessness. |
| Low-dose antipsychotics | Aggression, delusions | Sometimes used when safety is at risk. Prescribed with care. |
| Speech-language therapy | Primary progressive aphasia | Keeps language skills and adds new ways to communicate. |
| Physical & occupational therapy | Movement symptoms | May give modest relief and help people move more easily. |
No supplement or lifestyle change has been shown to stop FTD. Daily routines and activity may help people live better. We rate each by the strength of evidence.
The NIA advises a regular schedule, fewer distractions, simple choices, and not arguing with behavior the person cannot control.
In 105 people carrying FTD genes, those who were more active declined more slowly. This was an observational study, so it cannot prove activity caused the difference.
One small Italian Phase 2 trial (48 people) found less decline than placebo over 24 weeks. Not yet confirmed. Check with the care team before using it.
A randomized trial in 81 people found no benefit in FTD and more memory and thinking side effects than placebo.
No supplement has been shown to slow or prevent FTD. The NIA advises checking with a doctor before adding or stopping any supplement.
Compulsive eating is common in behavioral-variant FTD. The NIA suggests supervising meals, limiting food choices and locking cabinets if needed.
Be careful: before diagnosis, people with FTD usually cannot see that their behavior has changed, and they cannot control it. To keep everyone safe, caregivers may have to take on new responsibilities or arrange extra care. Ask the care team for help planning.
Centers recognized for expertise in this condition, and communities of people living with it.
A site of ALLFTD, the North American study of FTD, and home of UCSF's NIA-funded Alzheimer's Disease Research Center.
Both campuses are ALLFTD study sites, and Mayo Clinic runs an NIA-funded Alzheimer's Disease Research Center with sites in both cities.
A clinical and research unit for FTD and related disorders, including primary progressive aphasia, and an ALLFTD study site.
An ALLFTD study site and home of the Penn Alzheimer's Disease Research Center, which is funded by the NIA.
Coordinates GENFI, a group of research centers across Europe and Canada that studies genetic FTD.
These are centers recognized for expertise in this condition, not a ranking, and Cure Checker does not endorse or rate any facility. Outcomes depend on the individual. Ask your doctor which center fits your situation.
FTD often starts in midlife and changes behavior before memory, so families can feel alone. These groups know the disease. Most are free.
The main U.S. FTD organization, offering a helpline, support groups, education and research news.
Visit ↗A contact and research registry that lets people with FTD and their families hear about studies they may join.
Visit ↗A UK service with information and support for people living with FTD, familial FTD and other rare dementias.
Visit ↗Many private caregiver groups exist. This link searches Facebook (a login is required).
Search Facebook ↗Before you join: support groups share experiences, not medical advice. Check anything about treatment with your doctor. Protect your privacy, and never share passwords or financial details. Cure Checker isn't affiliated with these groups.
We found no country with a drug approved to slow FTD. Experimental progranulin treatments are being tested in North America, Europe and South America.
| Treatment | U.S. | EU | UK | Canada | Japan | S. Korea | China | Australia | Switz. |
|---|---|---|---|---|---|---|---|---|---|
| Any approved FTD drugDisease-slowing | None | — | — | — | — | — | — | — | — |
| AVB-101Gene therapy · FTD-GRN | Trial | Trial | Trial | Trial | — | — | — | — | — |
| DNL593Progranulin · FTD-GRN | Trial | Trial | Trial | — | — | — | — | — | — |
| LatozinemabPhase 3 failed 2025 | Stopped | — | — | — | — | — | — | — | — |
GENFI follows families with C9orf72, GRN and MAPT changes. Its 2026 survival study gives future trials better ways to measure whether a drug works.
Registered sites are listed in Poland, the UK, Spain, Belgium, Italy, the Netherlands, Sweden, the U.S. and Canada.
Registered sites include Italy, France, Spain, Belgium, Portugal, Türkiye, Brazil and Colombia. Results are expected in 2027.
In FTD, nerve cells in the frontal and temporal lobes stop working and die. The proteins tau and TDP-43 build up in abnormal forms. In most cases the cause is unknown, but about one in three cases is inherited.
Live numbers and the newest entries from the world's main trial registries and medical databases. Most of this loads fresh each time you open the page.
Loading live data from ClinicalTrials.gov…
Loading…
Loading…
Loading…
| Medicine | Brand | FDA application | Original approval |
|---|
From Drugs@FDA via FDA's openFDA service. Some older brands are missing from FDA's open data, and newly approved drugs can take a few weeks to appear. An approval may be for a different disease than this one.
The WHO's ICTRP gathers trials from registries worldwide, including China, Japan, India, Iran, Australia and Brazil. Cochrane CENTRAL and OpenMD don't allow automated access, so they're linked here for you to search directly.
This organization helps people with FTD and their care partners pay for care and costs. Funds are limited and rules vary, so contact it directly.
Pays back up to $500 a family each year for in-home care, adult day services, short overnight stays, counseling or self-care, for costs after the grant is approved. Families already getting respite through hospice, Medicaid, the VA or other public benefits can't apply. One application per July-to-June year.
See the grant ↗Pays back up to $500 for goods or services the person chooses, such as communication devices, transportation, companion care, insurance copays, medicines, therapies or home changes. One application per July-to-June year.
See the grant ↗Before you apply: Cure Checker does not run, verify or endorse these organizations, and being listed is not a promise of help. Funds are limited and rules change, so confirm eligibility and details with each organization. Be careful of anyone who asks for payment up front or for your bank login to 'release' a grant.
Everything this report is based on, grouped by section. Checked October 4, 2026.
Not individually cited: the "Be careful" note, the daily-care rows and the cause pathway come from the two NIA pages listed above. The AFTD pages block automated checks, so their existence was confirmed through search results, not opened directly. No Reddit community is listed because none could be confirmed. Drugs@FDA lists no product for latozinemab. Whether any drug is approved to slow FTD outside the U.S. was not checked regulator by regulator, so those cells show "—". The AVB-101, PBFT02 and DNL593 figures come from company releases and have not been peer-reviewed. Expert care centers: No official FTD center-of-excellence designation could be verified, so these are listed for ALLFTD or GENFI study roles and NIA-funded research centers. The University College London entry rests on GENFI's own site. Financial help: checked October 6, 2026. Only one qualifying organization was found. AFTD's pages block automated checks and were read with a headless browser. AFTD's Comstock Travel Grant was left out because from July 1, 2026 it only covers travel to AFTD's Education Conference.